The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 30, 2024

Filed:

Nov. 08, 2018
Applicants:

Fred Hutchinson Cancer Center, Seattle, WA (US);

Massachusetts Institute of Technology, Cambridge, MA (US);

Inventors:

Damian J. Green, Seattle, WA (US);

Yukang Lin, Issaquah, WA (US);

Oliver W. Press, Seattle, WA (US);

Alice Tzeng, Beachwood, OH (US);

Karl Dane Wittrup, Boston, MA (US);

Assignees:
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 39/395 (2006.01); A61K 31/203 (2006.01); A61K 45/06 (2006.01); A61K 51/04 (2006.01); A61P 35/00 (2006.01); C07K 16/28 (2006.01); C07K 16/44 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2896 (2013.01); A61K 31/203 (2013.01); A61K 39/3955 (2013.01); A61K 45/06 (2013.01); A61K 51/0482 (2013.01); A61P 35/00 (2018.01); C07K 16/2878 (2013.01); C07K 16/44 (2013.01); A61K 2039/505 (2013.01); C07K 2317/31 (2013.01); C07K 2317/622 (2013.01);
Abstract

The present disclosure provides compositions and methods for improved pre-targeted radioimmunotherapeutics (PRIT) to treat various hematological disorders, such as B cell hyperproliferative disorders and solid tumors. The disclosed compositions include bispecific antibody compositions having a first domain that specifically bind to an antigen such as CD38, BCMA, Muc1, GPRC5D, or Slam7, and a second domain that specifically binds to a radioactive ligand. Methods include administering the disclosed bispecific antibody reagent and separately administering the radioactive ligand. In some embodiments, a clearing agent is also administered. In some embodiments, the therapeutic methods comprise administering a combination of two or more bispecific antibody reagents. In some embodiments, an enhancing agent, such as ATRA, gamma secretase inhibitor, or dextramethasone, is also administered to enhance expression of the target antigen on the target cells.


Find Patent Forward Citations

Loading…